electroCore (ECOR) Stock Price, News & Analysis

Company Overview

electroCore, Inc. is a commercial-stage bioelectronic medicine company focused on the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies. Founded in 2006, the company has its headquarters in Basking Ridge, New Jersey, and was established with the aim of harnessing the therapeutic benefits of neuromodulation without the need for implantable devices. Since its inception, electroCore has advanced a pipeline of products designed to address a range of neurological and inflammatory conditions.

The company’s flagship product, gammaCore, is a handheld, battery-powered device that delivers controlled electrical stimulation to the cervical branch of the vagus nerve. gammaCore has received regulatory clearances in the United States, Europe and other markets for the acute and preventive treatment of migraine and cluster headaches. The therapy is administered by placing the device against the side of the neck, offering patients a drug-free alternative that can be self-administered in home or clinical settings.

electroCore has established a growing commercial presence in North America and Europe through a combination of direct sales, specialty distributors and partnerships with healthcare providers. The company continues to pursue label expansions and additional regulatory approvals in other indications, including inflammatory and respiratory disorders. Clinical programs are underway to explore gammaCore’s potential in conditions such as gastrointestinal diseases, heart failure and depression, reflecting the broader applicability of nVNS technology.

Under the leadership of Chairman and Chief Executive Officer Jonathan Sackier, electroCore’s management team brings experience in medical devices, pharmaceuticals and global commercialization. The company maintains a focus on scaling operations, strengthening payer reimbursement pathways and advancing research collaborations. With an emphasis on innovation and patient access, electroCore seeks to establish nVNS as a foundational therapy in bioelectronic medicine.

Key Stats

• Today's Range: $6.17 to $7.95
• 50-Day Range: $4.61 to $7.57
• 52-Week Range: $4.47 to $19.49
• Volume: 439,167 shs
• Average Volume: 102,151 shs
• Market Capitalization: $53.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.50
• Consensus Rating: Buy

electroCore Stock Analysis - MarketRank™

electroCore scored higher than 46% of companies evaluated by MarketBeat, and ranked 586th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

electroCore has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

electroCore has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for electroCore are expected to grow in the coming year, from ($1.49) to ($0.46) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of electroCore is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of electroCore is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

electroCore has a P/B Ratio of 6.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.52% of the float of electroCore has been sold short.

Short Interest Ratio / Days to Cover

electroCore has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in electroCore has recently decreased by 1.79%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

electroCore does not currently pay a dividend.

Dividend Growth

electroCore does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.52% of the float of electroCore has been sold short.

Short Interest Ratio / Days to Cover

electroCore has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in electroCore has recently decreased by 1.79%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 3 people have searched for ECOR on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added electroCore to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, electroCore insiders have bought more of their company's stock than they have sold. Specifically, they have bought $56,718.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

19.70% of the stock of electroCore is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 26.74% of the stock of electroCore is held by institutions.

ECOR Stock Analysis - Frequently Asked Questions

How have ECOR shares performed this year?

electroCore's stock was trading at $16.21 at the beginning of the year. Since then, ECOR shares have decreased by 57.3% and is now trading at $6.92.

How were electroCore's earnings last quarter?

electroCore, Inc. (NASDAQ:ECOR) issued its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.09. The business earned $6.72 million during the quarter, compared to analysts' expectations of $6.93 million. electroCore had a negative trailing twelve-month return on equity of 149.04% and a negative net margin of 46.24%.
Read the conference call transcript.

When did electroCore's stock split?

electroCore's stock reverse split before market open on Tuesday, February 14th 2023.The 1-15 reverse split was announced on Tuesday, February 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did electroCore IPO?

electroCore (ECOR) raised $64 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 4,300,000 shares at $14.00-$16.00 per share. Evercore ISI and JMP Securities acted as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of electroCore?

Shares of ECOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of electroCore own?

Based on aggregate information from My MarketBeat watchlists, some other companies that electroCore investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Tesla (TSLA), CymaBay Therapeutics (CBAY) and GE Aerospace (GE).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:ECOR
• CIK: 1560258
• Web: www.electrocore.com
• Phone: (973) 290-0097
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $25.50
• High Stock Price Target: $26.00
• Low Stock Price Target: $25.00
• Potential Upside/Downside: +318.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.89 million
• Net Margins: -46.24%
• Pretax Margin: -46.31%
• Return on Equity: -149.04%
• Return on Assets: -61.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.52
• Quick Ratio: 1.30

Sales & Book Value

• Annual Sales: $25.18 million
• Price / Sales: 1.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.13 per share
• Price / Book: 5.39

Miscellaneous

• Outstanding Shares: 7,420,000
• Free Float: 5,959,000
• Market Cap: $45.19 million
• Optionable: Not Optionable
• Beta: 0.80